Latest news
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpaceBioSpace · Fri, 07 Aug 2026 10:26:31 GMTARCT: Advanced rare disease pipeline and regained global vaccine rights, with strong cash runway through 2028 - TradingViewTradingView · Thu, 06 Aug 2026 22:19:18 GMTARCT: Advanced rare disease pipeline, regained key vaccine rights, and secured cash runway through 2028 - TradingViewTradingView · Thu, 06 Aug 2026 20:08:15 GMTTarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition - ReutersReuters · Thu, 06 Aug 2026 13:55:38 GMTZVRA: Revenue growth and strong liquidity support ongoing rare disease pipeline advancement - TradingViewTradingView · Wed, 05 Aug 2026 21:20:16 GMTWhy payers should have these 3 pipeline drugs on their radar - Fierce HealthcareFierce Healthcare · Mon, 03 Aug 2026 19:38:03 GMTAscellaHealth Delivers Mid-Year Specialty Pharmacy Outlook to Help Payers Navigate Pipeline Innovation, Cost and Benefit Strategy - markets.businessinsider.commarkets.businessinsider.com · Fri, 31 Jul 2026 02:46:16 GMTDoes BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy? - simplywall.stsimplywall.st · Thu, 30 Jul 2026 07:15:07 GMT